GD2 positivity in bone marrow cells may represent a useful prognostic marker for patients with non-metastatic neuroblastoma [12], and B4GALNT1 has been suggested to be a pan-cancer biomarker [13]. The gene discussed is B4GALNT1; the disease is neuroblastoma.